EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment



Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment



Women's Health 2(3): 341-349



Ibandronate is a potent nitrogen-containing bisphosphonate that is currently available as a daily and once-monthly oral formulation for the treatment and prevention of osteoporosis. It has recently been approved for intermittent intravenous administration. The oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe (BONE), Monthly Oral iBandronate In LadiEs (MOBILE), and Dosing IntraVenous Administration (DIVA) trials demonstrated that long-term daily and intermittent administration of ibandronate was efficacious for increasing bone mineral density and reducing markers of bone turnover. BONE demonstrated that ibandronate reduced the risk of new vertebral fractures and reduced the relative risk of nonvertebral fractures in higher-risk patients. Histomorphometric evaluations in the BONE and DIVA trials have demonstrated that bone quality is maintained following treatment. Giving patients the option of choosing their dose regimen and route of administration may increase overall adherence to treatment, leading to enhanced fracture protection in patients with osteoporosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 053653039

Download citation: RISBibTeXText

PMID: 19803906

DOI: 10.2217/17455057.2.3.341



Related references

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Treatment of corticoid-induced osteoporosis by 3-monthly intravenous ibandronate injections. Journal of Bone & Mineral Research 15(Suppl 1): S150, September, 2000

Ibandronate: Extending treatment options with oral monthly and quarterly IV injection dosing, from bone quality to antifracture protection - Introduction. 2007

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clinical Therapeutics 28(4): 475-490, 2006

New dosing options in osteoporosis treatment: clinical evidence on Risedronate 75mg monthly treatment. Clinical Cases in Mineral and Bone Metabolism 5(2): 155-158, 2008

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clinical Therapeutics 31(4): 751-761, 2009

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2(1): 3-18, 2008

Ibandronate: new options in the treatment of osteoporosis. Drugs of Today 39(11): 877-886, 2004

Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcified Tissue International 95(6): 557-563, 2015

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion 25(12): 2951-2960, 2010

Increase by 10% of spine bone mineral density and effect on bone markers of three monthly intravenous injections of ibandronate in osteoporosis in men with Klinefelters syndrome. Journal of Bone & Mineral Research 15(Suppl 1): S226, September, 2000

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. Journal of Bone and Mineral Research 16(10): 1871-1878, 2001